CVS Breaks Itself Up, and Keeps the Parts That Matter

On November 4, 2026, one day after a midterm election that returned control of Congress to Democrats, CVS Health confirmed it would split into two publicly traded companies by the first half of 2028. One company retains the CVS Health name along with the Aetna insurance business, the Caremark pharmacy benefit manager (PBM), and CVS Specialty. The other, called CVS Pharmacy, takes the roughly 9,000 retail stores, mail-order operations, and MinuteClinic. CEO David Joyner told analysts the company was acting "from a position of strength." The more useful question for patients is which businesses CVS chose to keep together, and why.

What CVS Divided, and What It Did Not

The division follows a clear logic. CVS is keeping Aetna, Caremark, and CVS Specialty under one roof, alongside the Oak Street Health clinics and Signify Health, with Joyner leading that company. Prem Shah will run CVS Pharmacy, which inherits the retail stores, mail order, MinuteClinic, and the Health100 technology unit. Shareholders will own both companies in a tax-free transaction. What remains after the split is an insurer, a PBM, and a specialty pharmacy operating together, a structure that, as Adam Fein of the Drug Channels Institute observed, looks a lot like Cigna.

Joyner was candid that the integration patients and advocates worry about survives the breakup. The products CVS built as a combined company "are things that are going to be preserved in commercial agreements between the two organizations. So we don't need the integration of an operating structure," he said. The company is separating its legal entities while contracting to keep the commercial relationship running.

The Pressure That Came First

CVS did not arrive at this decision in a vacuum. All 50 states have passed nearly 250 laws targeting PBM practices, and two of them, Arkansas and Tennessee, have enacted measures barring a single company from owning both a PBM and a pharmacy, though both laws face federal legal challenges. The Federal Trade Commission settled a case with CVS over the summer that restricts how Caremark deals with competing pharmacies. At the federal level, Senators Elizabeth Warren (D-Mass.) and Josh Hawley (R-Mo.) introduced the Break Up Big Medicine Act in February 2026, which would block an insurer or PBM from also owning a pharmacy.

Joyner told the Wall Street Journal that regulatory issues were not driving the decision. The chronology and the analysts suggest otherwise. Elizabeth Anderson of Evercore ISI wrote that shifting regulatory winds influenced the separation. Emma Freer, a healthcare policy analyst at the American Economic Liberties Project, was blunter: CVS is "trying to circumvent those efforts by breaking up on its own terms and dissuading lawmakers from pursuing more aggressive structural reforms." Tennessee's ownership law is scheduled to take effect in mid-2028, after the split is set to close. The reorganization is timed to arrive ahead of the rules written to constrain it.

The Specialty Pharmacy Tell

The clearest evidence of what this breakup is designed to do sits in what CVS kept. CVS Specialty remains with Caremark and Aetna, not with the retail pharmacy. Specialty medications, the high-cost treatments for cancer, multiple sclerosis, hormonal therapy, and weight loss, carry the richest margins in the portfolio. CVS spun off the retail business, which runs adjusted operating margins of roughly 4% to 5%. It kept the lever that moves money.

Retaining Caremark and CVS Specialty together preserves the conflict that reform efforts are chasing. Antonio Ciaccia of 46brooklyn Research explained that Caremark "has the ability to define what a specialty drug is and then rout the prescription through its preferred pharmacy." Douglas Hoey of the National Community Pharmacists Association warned that the specialty business "may use this new well to help replace some of those profits and revenue that might be dried up with these new regulations." Separate ownership of the retail stores does not end patient steering either. Caremark can continue to favor CVS pharmacies through preferred network arrangements; the difference is where the profit lands, not whether the steering happens.

What Patients Should Expect

Very little, according to the people who study this market. Roughly 25% of the country has prescriptions managed by CVS, and about 10% receive insurance from it. Dr. Mariana Socal of Johns Hopkins does not expect prices to fall, because she does not believe the split actually separates Caremark from CVS. "There is no change." What might lower costs, she said, is separating Caremark from Aetna, and that relationship stays intact. The one real gain is narrow. Freer noted that spinning off the retail pharmacies would "foreclose that particular avenue for that type of gaming," the practice of Caremark paying its affiliated CVS stores in ways that raise premiums and cost sharing. One avenue closes. The machinery that sets drug prices and directs where people fill prescriptions keeps running.

Why This Matters for Our Communities

People living with HIV, hepatitis C, and substance use disorder depend on the exact assets CVS declined to release. Specialty medications and 340B pricing are load-bearing for this care, and both remain bundled with the PBM and the insurer. CVS participates in 340B by providing pharmacy services to safety-net providers, and changes to manufacturer data-sharing and reimbursement could pressure that business in 2027. Wall Street read the announcement for what it is, sending shares down 12.5% and erasing more than $14 billion in value.

The incoming Congress should not mistake a corporate reorganization for structural reform. PBM legislation needs to reach specialty pharmacy ownership and preferred-network steering, not stop at the retail storefront. Regulators enforcing the Arkansas and Tennessee laws should examine the commercial agreements CVS plans to negotiate over the next 15 to 18 months for continued self-dealing. Ending the HIV Epidemic and HCV Elimination require breaking the pricing and steering apparatus that this split leaves in place. CVS moved its least profitable business out of the building and kept everything that drives cost. The policymakers who have spent years building the case for PBM reform should keep building it.

CVS moved its least profitable business out of the building and kept everything that drives cost.